BACKGROUND: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. METHODS: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. RESULTS: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. CONCLUSIONS: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs.

Masaryk Memorial Cancer Institute Regional Centre for Applied Molecular Oncology Zluty kopec 7 656 53 Brno Czech Republic

See more in PubMed

Ho YP, Au-Yeung SC, To KK. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Medicinal Research Reviews. 2003;23:633–655. doi: 10.1002/med.10038. PubMed DOI

Kozubik A, Vaculova A, Soucek K, Vondracek J, Turanek J, Hofmanova J. Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Metal-Based Drugs. 2008;2008:417897. PubMed PMC

Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clinical Cancer Research. 2008;14:1633–1638. doi: 10.1158/1078-0432.CCR-07-2176. PubMed DOI

Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. Journal of Clinical Oncology. 1999;17:3822–3827. PubMed

Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opinion on Investigational Drugs. 2000;9:1373–1382. doi: 10.1517/13543784.9.6.1373. PubMed DOI

Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D. et al.Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. Journal of Medicinal Chemistry. 2004;47:761–763. doi: 10.1021/jm030858+. PubMed DOI

Turanek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, L SI, Kozubik A, Sova P. et al.New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs. 2004;15:537–543. doi: 10.1097/01.cad.0000127147.57796.e5. PubMed DOI

Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecologic Oncology. 2006;102:32–40. doi: 10.1016/j.ygyno.2005.11.016. PubMed DOI

Cermanova J, Chladek J, Soval P, Kroutil A, Semerad M, Berankova Z, Siroky P, Surova I. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. Methods and Findings in Experimental and Clinical Pharmacology. 2004;26:679–685. doi: 10.1358/mf.2004.26.9.872565. PubMed DOI

Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anti-Cancer Drugs. 2005;16:653–657. doi: 10.1097/00001813-200507000-00010. PubMed DOI

Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anti-Cancer Drugs. 2006;17:201–206. doi: 10.1097/00001813-200602000-00012. PubMed DOI

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279. doi: 10.1038/sj.onc.1206933. PubMed DOI

Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Investigational New Drugs. 2007;25:435–443. doi: 10.1007/s10637-007-9062-7. PubMed DOI

Roubalova E, Kvardova V, Hrstka R, Borilova S, Michalova E, Dubska L, Muller P, Sova P, Vojtesek B. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Investigational New Drugs. 2010;28:445–453. doi: 10.1007/s10637-009-9270-4. PubMed DOI

Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anti-Cancer Drugs. 2008;19:369–379. doi: 10.1097/CAD.0b013e3282f7f500. PubMed DOI

Kvardova V, Hrstka R, Walerych D, Muller P, Matoulkova E, Hruskova V, Stelclova D, Sova P, Vojtesek B. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer. 2010;9:147. doi: 10.1186/1476-4598-9-147. PubMed DOI PMC

Sova P, Mistr A, Kroutil A, Semerad M, Chlubnova H, Hruskova V, Chladkova J, Chladek J. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) Cancer Chemotherapy and Pharmacology. 2011;67:1247–1256. doi: 10.1007/s00280-010-1411-0. PubMed DOI

Pilny R, Bouchal P, Borilova S, Ceskova P, Zaloudik J, Vyzula R, Vojtesek B, Valik D. Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices. Clinical Chemistry. 2006;52:2115–2116. doi: 10.1373/clinchem.2006.073841. PubMed DOI

Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual Review of Pathology. 2011;6:345–364. doi: 10.1146/annurev-pathol-011110-130303. PubMed DOI

Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R. Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Research. 2008;10:R48. PubMed PMC

Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics. 2005;5:3790–3797. doi: 10.1002/pmic.200401205. PubMed DOI

Schagger H. Tricine-SDS-PAGE. Nature Protocols. 2006;1:16–22. doi: 10.1038/nprot.2006.4. PubMed DOI

Matsui NM, Smith-Beckerman DM, Epstein LB. In: 2-D Proteome Analysis Protocols. L AJ, editor. Vol. 112. Totowa, New Yersey: Humana Press; 1999. Staining of Preparative 2-D Gels; pp. 307–311.

Havlasova J, Hernychova L, Brychta M, Hubalek M, Lenco J, Larsson P, Lundqvist M, Forsman M, Krocova Z, Stulik J, Macela A. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics. 2005;5:2090–2103. doi: 10.1002/pmic.200401123. PubMed DOI

Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. Journal of Clinical Investigation. 1968;47:2025–2044. doi: 10.1172/JCI105889. PubMed DOI PMC

Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, Drew PA. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncology Reports. 2009;21:1067–1073. PubMed

Zovich DC, Orologa A, Okuno M, Kong LW, Talmage DA, Piantedosi R, Goodman DS, Blaner WS. Differentiation-dependent expression of retinoid-binding proteins in BFC-1 beta adipocytes. Journal of Biological Chemistry. 1992;267:13884–13889. PubMed

Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356–362. doi: 10.1038/nature03711. PubMed DOI

Zanotti G, Ottonello S, Berni R, Monaco HL. Crystal-Structure of the Trigonal Form of Human Plasma Retinol-Binding Protein at 2.5-Angstrom Resolution. Journal of Molecular Biology. 1993;230:613–624. doi: 10.1006/jmbi.1993.1173. PubMed DOI

Cross-Reference To Related Source. http://www.freepatentsonline.com/y2008/0033053.html

Hung YC, Huang GS, Lin LW, Hong MY, Se PS. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food and Chemical Toxicology. 2007;45:1123–1130. doi: 10.1016/j.fct.2006.12.017. PubMed DOI

ExPASy. http://www.expasy.org/cgi-bin/protparam1?P04916@noft@

Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Petrak J. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports. in press . PubMed

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome